<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153983</url>
  </required_header>
  <id_info>
    <org_study_id>140119</org_study_id>
    <secondary_id>14-CH-0119</secondary_id>
    <secondary_id>ZIAHD000641-23</secondary_id>
    <nct_id>NCT02153983</nct_id>
  </id_info>
  <brief_title>Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome</brief_title>
  <official_title>Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Being overweight may cause low-level inflammation. This inflammation may cause some of the
      medical problems of obesity, like high blood sugar (diabetes) and heart disease. This study
      will test whether a medication called colchicine can improve metabolism in adults who are
      overweight but have not yet developed diabetes.

      Objectives:

      - To learn whether colchicine improves sugar regulation and metabolism.

      Eligibility:

      - Healthy overweight adults18 to 100 years old.

      Design:

        -  Participants must fast before each visit, including the screening visit.

        -  Participants will be screened with blood tests,urine tests, medical history, and
           physical exam. They will have to drink sugar water, and have blood drawn to find out if
           they are healthy.

        -  For visit 1, participants will have a medical history and physical exam and answer
           questions. They will have blood taken with an intravenous (IV) line, give urine sample,
           and give 2 stool samples..

        -  Also, subjects will get sugar water through one IV. Blood will be drawn from the other.
           This measures sugar and insulin levels. During this, participants will lie in a bed and
           can watch TV.

        -  Participants will have a full-body X-ray, lying on a table while a camera passes over
           them. They will also have an abdominal CT scan, lying on a table that moves through a
           ring that takes pictures.

        -  Participants will have a small fat tissue sample taken from their abdomen. It is like
           getting a mini-liposuction.

        -  Participants will be given the study drug or placebo. They will take it twice daily for
           3 months.

        -  For visit 2, participants will have blood tests, urine tests, medical history, and
           physical exam.

        -  For visit 3, participants will repeat the tests in visit 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity affects one-third of the adult U.S. population and is a major risk factor for the
      development of type 2 diabetes and cardiovascular disease. Mouse models and human data
      suggest that obesity-induced chronic inflammation is one mechanism promoting
      obesity-associated comorbid conditions. In obesity, innate immunity is activated by
      circulating molecules such as fatty acids and cholesterol crystals bind to nucleotide-binding
      oligomerization (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) receptors in
      adipocyte tissue macrophages (ATMs). This binding stimulates NLRP3 oligomerization,
      inflammasome formation, and proinflammatory cytokine activation. The resultant inflammatory
      cascade leads to insulin resistance and decreased pancreatic beta-cell reserve. It has been
      proposed that the suppression of this chronic low-level inflammatory state may impede the
      onset of diabetes and cardiovascular disease.

      Recent studies have shown colchicine, a potent microtubule inhibitor commonly used for the
      treatment of gout and some rare inflammatory conditions, disrupts intracellular localization
      of NLRP3, thereby blocking inflammasome assembly. As there are limited medical therapies
      proven effective to improve obesity-related metabolic dysregulation, we propose to determine
      the efficacy of colchicine 0.6 mg twice daily in non-diabetic obese adults with metabolic
      syndrome. We will conduct a randomized, double-blinded, placebo-controlled pilot trial of
      colchicine in forty subjects. We will study changes in insulin resistance, beta-cell reserve,
      and systemic inflammation. Using adipose tissue obtained from biopsies, we will also study
      colchicine s local effects on inflammation and insulin resistance. Should results prove
      promising, this pilot study will allow determination of the sample size needed for an
      adequately powered study of the effects of colchicine in obese adults with metabolic
      syndrome.

      Seven patients with diet-controlled type 2 diabetes will be given open-label colchicine and
      followed as described above. We also plan to perform baseline evaluations on 40 subjects who
      are not eligible for the treatment protocol. This group will consist of non-obese adults,
      obese adults who are not insulin-resistant, and adults with diet-controlled type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 31, 2014</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Note that only 2 of the arms are randomized. Three arms are observational and one is open-label treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In the randomized portion of the trial, all participants, Study Site staff, and pathology and laboratory personnel are blinded to the individual assignment of the order in which colchicine and placebo are administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity From FSIVGTT</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change (3 month minus minus baseline) in insulin sensitivity value, calculated from frequently-sampled intravenous glucose tolerance tests by Bergman's Minimal Model using intent-to-treat. Higher values represent a better outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR Index</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change (3 month minus minus baseline) in calculated homeostasis model of insulin sensitivity, calculated from derived from fasting glucose and insulin values = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5) using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C-reactive Protein</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change (3 month minus minus baseline) in High-Sensitivity C-reactive protein concentrations using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Obese Adults with Metabolic Syndrome Randomized to Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Adults with Metabolic Syndrome Randomized to Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evaluation Only Non-obese Adults</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evaluation Only Obese Adults Not Randomized</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evaluation Only Adults with Type 2 Diabetes</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.6Mg Cap</intervention_name>
    <description>Colchicine 0.6 mg given twice daily</description>
    <arm_group_label>Obese Adults with Metabolic Syndrome Randomized to Colchicine</arm_group_label>
    <other_name>RCT Colchicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules given</intervention_name>
    <description>Placebo capsules given twice daily</description>
    <arm_group_label>Obese Adults with Metabolic Syndrome Randomized to Placebo</arm_group_label>
    <other_name>RCT Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.6Mg Tab</intervention_name>
    <description>Open-label colchicine</description>
    <arm_group_label>Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine</arm_group_label>
    <other_name>Open-Label Colchicine 0.6 mg given twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA FOR SUBJECTS RANDOMIZED TO COLCHICINE or PLACEBO::

        Subjects will qualify for randomization to colchicine or placebo if they meet the following
        criteria:

          -  Good general health. In general subjects should take no medications. However,
             individuals taking medications for obesity-related co-morbid conditions, who have not
             had changes in dosage for more than 3 months, may be included, at the discretion of
             the principal investigator.

          -  Obesity, defined as a body mass index (BMI) greater than or equal to 30 kg/m^2, but
             weight less than 450 lbs in order for subjects to undergo Dual-Energy X-ray
             Absorptiometry (DXA) scanning.

          -  Age 18 to 100 years.

          -  Metabolic Syndrome defined as any 3 of the following 5:

               -  FPG greater than or equal to 100 mg/dl, or Impaired Glucose Tolerance (Glucose
                  greater than or equal to 140 mg/dl at 2 hours of OGTT)

               -  Triglycerides greater than or equal to 150 mg/dl, or on treatment

               -  Waist Circumference: Men greater than or equal to 40 in (greater than or equal to
                  102 cm); Women greater than or equal to 35 in (greater than or equal to 88 cm)

               -  Reduced HDL-C: Men &lt; 40 mg/dl; Women &lt; 50 mg/dl, or on treatment

               -  Hypertension: greater than or equal to 130 mmHg systolic, or greater than or
                  equal to 85 mmHg diastolic, or on treatment

          -  HOMA-IR greater than or equal to 2.6. Our goal is to enroll participants who have
             pre-existing insulin resistance.

          -  high sensitivity C-reactive protein (hs-CRP) greater than or equal to 2.0 mg/L. We aim
             to recruit participants with increased baseline level of inflammation. Individuals
             with hsCRP above 2.0 mg/L have been shown to have an increased risk for cardiovascular
             events.

        EXCLUSION CRITERIA FOR SUBJECTS RANDOMIZED TO COLCHICINE OR PLACEBO:

          -  Type 2 diabetes mellitus, as determined by either having:

               -  Clear clinical diagnosis of diabetes, such as a patient in a hyperglycemic crisis
                  or classic symptoms of hyperglycemia and a random plasma glucose greater than or
                  equal to 200 mg/dL

               -  Two of the following three:

                    -  Fasting plasma glucose greater than or equal to 126 mg/dL

                    -  Hemoglobin A1c greater than or equal to 6.5%

                    -  An oral glucose tolerance test glucose concentration of greater than or
                       equal to 200 mg/dL at 2 hours.

               -  One of the above three criteria (bi.-biii.) meeting the T2DM cutoff on two
                  different days. If only one of the above three criteria (bi.-biii.) meet the T2DM
                  threshold during the Screening Visit, that test will be repeated on another day
                  to determine if the subject has T2DM or not. As per ADA guidelines, The diagnosis
                  [of T2DM] is made on the basis of the confirmed test.Moreover, because HbA1c has
                  been shown to be higher in African Americans (AA) as compared to other races for
                  the same glycemia, non-diabetic AA may be unfairly excluded by their HbA1c alone.
                  Therefore, for AA subjects, if their 2 hour OGTT and fasting glucoses are in the
                  non-diabetic range, and the HbA1c is &lt; 7.0%, we will consider them non-diabetic.

          -  Presence of a significant active or chronic illness likely to limit life span and/or
             increase risk of intervention, including renal (GFR less than or equal to 60
             ml/min/1.73m2), cardiovascular, hepatic (other than obesity-related steatosis),
             gastrointestinal, immunologic, endocrinologic (e.g. Cushing syndrome), pulmonary
             (other than either asthma not requiring continuous medication or sleep apnea-related
             disorders), or other disorders at the discretion of the investigators.

          -  Recent use of colchicine or anorexiant medications in the last 3 months.

          -  Known allergy to colchicine.

          -  Previous history of agranulocytosis, gout, or significant myositis.

          -  Females who are pregnant, planning to become pregnant, currently nursing an infant, or
             have irregular menses, defined as cycles less than 21 days or greater than 45 days.

          -  Individuals who have current substance abuse or a psychiatric disorder or any other
             condition that in the opinion of the investigators would impede competence,
             compliance, or participation in the study.

          -  Subjects who regularly use prescription medications unrelated to the complications of
             obesity, especially those known to affect enzymes involved in colchicine metabolism,
             such as CYP3A4 or P-glycoprotein (P-gp) . Oral contraceptive use will be permitted,
             provided the contraceptive has been used for at least two months before starting study
             medication. The use of over-the-counter and prescription medications will be reviewed
             on a case-by-case basis; depending on the medication, subjects who have continued to
             take prescription medication or have stopped taking an exclusionary medication for at
             least 3 months prior to study entry may be eligible .

          -  Participation in a formal weight loss program (e.g. Weight Watchers) or recent weight
             change of more than 3% of body weight in the past two months.

          -  Use of anti-inflammatory medications (e.g. prednisone, NSAIDs) chronically or in the
             last 7 days prior to fat biopsy.

          -  History of keloid formation.

          -  Current users of tobacco or nicotine products (e.g. nicotine patch, e-cigarettes).

        INCLUSION CRITERIA FOR SUBJECTS WHO ARE EVALUATED BUT NOT ELIGIBLE FOR RANDOMIZATION:

        Subjects will qualify for the Evaluation-only arm if they meet the following criteria:

          -  Good general health. In general subjects should take no medications. The use of
             over-the-counter and prescription medications will be reviewed on a case-by-case
             basis; depending on the medication, subjects who have continued to take prescription
             medication or have stopped taking an exclusionary medication for at least 3 months
             prior to study entry may be eligible.

          -  Weight less than 450 lbs in order for subjects to undergo Dual-Energy X-ray
             Absorptiometry (DXA) scanning.

          -  Age 18 years to 100 years.

        EXCLUSION CRITERIA FOR SUBJECTS WHO ARE EVALUATED BUT NOT ELIGIBLE FOR RANDOMIZATION:&lt;TAB&gt;

          -  Type 2 diabetes mellitus that is not well controlled with diet alone: subjects taking
             an antidiabetic medication (e.g. metformin, insulin, sulfonylureas, etc.) or having a
             Hemoglobin A1c &gt; 9.0%

          -  Presence of a significant active or chronic illness likely to limit life span and/or
             increase risk of intervention, including renal (GFR less than or equal to 60
             ml/min/1.73m2), cardiovascular, hepatic (other than obesity-related steatosis),
             gastrointestinal, immunologic, endocrinologic (e.g. Cushing syndrome), pulmonary
             (other than either asthma not requiring continuous medication or sleep apnea-related
             disorders), or other disorders at the discretion of the investigators.

          -  Recent use of colchicine or anorexiant medications in the last 3 months.

          -  Females who are pregnant, planning to become pregnant, or are currently nursing an
             infant.

          -  Individuals who have current substance abuse or a psychiatric disorder or any other
             condition that in the opinion of the investigators would impede competence,
             compliance, or participation in the study.

          -  Participation in a formal weight loss program (e.g. Weight Watchers) or recent weight
             change of more than 3% of body weight in the past two months.

          -  Use of anti-inflammatory medications (e.g. prednisone, NSAIDs) chronically or in the
             last 7 days prior to fat biopsy.

          -  History of keloid formation.

          -  Current users of tobacco or nicotine products (e.g. nicotine patch, e-cigarettes).

        INCLUSION CRITERIA FOR SUBJECTS WITH DIET-CONTROLLED T2DM

        Subjects will qualify for the Open Label arm if they meet the following criteria:

          -  A diagnosis of T2DM.

               -  Not on any diabetic/hypoglycemic agents

               -  Not having an alternate cause of hyperglycemia (e.g. T1DM, glucocorticoidinduced,
                  lipodystrophy, acromegaly, etc.)

          -  Hemoglobin A1c less than or equal to 9.0%

          -  Good general health. In general subjects should take no medications. The use of
             over-the-counter and prescription medications will be reviewed on a case-by-case
             basis; depending on the medication, subjects who have continued to take prescription
             medication or have stopped taking an exclusionary medication for at least 3 months
             prior to study entry may be eligible

          -  Age greater than or equal to 18 to 100 years.

          -  Obesity, defined as a body mass index (BMI) greater than or equal to 30 kg/m2, but
             weight less than 450 lbs in order for subjects to undergo Dual-Energy X-ray
             Absorptiometry (DXA) scanning.

          -  Metabolic Syndrome

        (Any 3 of the following 5):

          -  FPG greater than or equal to100 mg/dl or Impaired Glucose Tolerance (Glucose greater
             than or equal to 140 mg/dl at 2 hours of OGTT)

          -  Triglycerides greater than or equal to 150 mg/dl, or on treatment

          -  Waist Circumference: Men greater than or equal to 40 in (greater than or equal to 102
             cm); Women greater than or equal to 35 in (greater than or equal to 88 cm)

          -  Reduced HDL-C: Men &lt; 40 mg/dl; Women &lt; 50 mg/dl, or on treatment

          -  Hypertension: greater than or equal to 130 mmHg systolic, or greater than or equal to
             85 mmHg diastolic, or on treatment

               -  HOMA-IR greater than or equal to 2.6. Our goal is to enroll participants who have
                  pre-existing insulinresistance.

               -  hsCRP greater than or equal to 2.0 mg/L. We aim to recruit participants with
                  increased baseline level of inflammation. Individuals with hsCRP above 2.0 mg/L
                  have been shown to have an increased risk for cardiovascular events.

        EXCLUSION CRITERIA FOR SUBJECTS WITH DIET-CONTROLLED T2DM

          -  T2DM that is not well controlled with diet alone: subjects will not be eligible if
             they take an anti-diabetic medication (e.g. metformin, insulin, sulfonylurea, etc.),
             or have HbA1c &gt;9%.

          -  Presence of a significant active or chronic illness likely to limit life span and/or
             increase risk of intervention, including renal (GFR less than or equal to 30
             ml/min/1.73m2), cardiovascular, hepatic (other than obesity-related steatosis),
             gastrointestinal, immunologic, endocrinologic (e.g. Cushing syndrome), pulmonary
             (other than either asthma not requiring continuous medication or sleep apnea-related
             disorders), or other disorders at the discretion of the investigators.

          -  Recent use of colchicine or anorexiant medications in the last 3 months.

          -  Known allergy to colchicine.

          -  Previous history of agranulocytosis, gout, or significant myositis.

          -  Females who are pregnant, planning to become pregnant, currently nursing an infant, or
             have irregular menses, defined as cycles less than 21 days or greater than 45 days.

          -  Individuals who have current substance abuse or a psychiatric disorder or any other
             condition that in the opinion of the investigators would impede competence,
             compliance, or participation in the study.

          -  Subjects who regularly use prescription medications unrelated to the complications of
             obesity, especially those known to affect enzymes involved in colchicine metabolism,
             such as CYP3A4 or P-glycoprotein (P-gp). Oral contraceptive use will be permitted,
             provided the contraceptive has been used for at least two months before starting study
             medication. The use of over-the-counter and prescription medications will be reviewed
             on a case-by-case basis; depending on the medication, subjects who have continued to
             take prescription medication or have stopped taking an exclusionary medication for at
             least 3 months prior to study entry may be eligible.

          -  Participation in a formal weight loss program (e.g. Weight Watchers) or recent weight
             change of more than 3% of body weight in the past two months.

          -  Use of anti-inflammatory medications (e.g. prednisone, NSAIDs) chronically or in the
             last 7 days prior to fat biopsy.

          -  History of keloid formation.

          -  Current users of tobacco or nicotine products (e.g. nicotine patch, e-cigarettes).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack A Yanovski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-CH-0119.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011 May;12(5):408-15. doi: 10.1038/ni.2022. Epub 2011 Apr 10.</citation>
    <PMID>21478880</PMID>
  </reference>
  <reference>
    <citation>Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011 Feb;17(2):179-88. doi: 10.1038/nm.2279. Epub 2011 Jan 9.</citation>
    <PMID>21217695</PMID>
  </reference>
  <reference>
    <citation>Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Med Hypotheses. 2016 Jul;92:67-73. doi: 10.1016/j.mehy.2016.04.039. Epub 2016 Apr 25.</citation>
    <PMID>27241260</PMID>
  </reference>
  <results_reference>
    <citation>Demidowich AP, Levine JA, Onyekaba GI, Khan SM, Chen KY, Brady SM, Broadney MM, Yanovski JA. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes Obes Metab. 2019 Jul;21(7):1642-1651. doi: 10.1111/dom.13702. Epub 2019 Apr 2.</citation>
    <PMID>30869182</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 31, 2014</study_first_submitted>
  <study_first_submitted_qc>May 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <results_first_submitted>June 13, 2019</results_first_submitted>
  <results_first_submitted_qc>July 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 27, 2019</last_update_submitted>
  <last_update_submitted_qc>July 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>Jack Yanovski, M.D.</investigator_full_name>
    <investigator_title>Chief, Section on Growth and Obesity</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Colchicine</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual-level data for the primary and secondary outcomes will be made available upon request. PII will be removed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>in July 2021, and then indefinitely</ipd_time_frame>
    <ipd_access_criteria>Approval of the PI</ipd_access_criteria>
    <ipd_url>https://dash.nichd.nih.gov/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02153983/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02153983/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>213 adults were screened in the clinic and signed consent forms, of whom 77 were found eligible and studied with protocols.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
          <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation given twice daily</description>
        </group>
        <group group_id="P2">
          <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
          <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
        </group>
        <group group_id="P3">
          <title>Open Label Patients With Type 2 Diabetes</title>
          <description>Patients with diet-controlled type 2 dabetes, given open-label colchicine tablets 0.6 mg twice-daily</description>
        </group>
        <group group_id="P4">
          <title>Evaluation Only Non-obese Adults</title>
          <description>Adults without obesity, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
        <group group_id="P5">
          <title>Evaluation Only Obese Adults</title>
          <description>Adults with obesity, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
        <group group_id="P6">
          <title>Evaluation Only Adults With Type 2 Diabetes</title>
          <description>Adults with Diet-controlled Type 2 Diabetes, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants are adults with high C-reactive protein, obesity, and metabolic syndrome. Open-label patients have Type 2 diabetes. Evaluation Only participants did not have to have obesity, diabetes, metabolic syndrome, or high C-reactive protein.</population>
      <group_list>
        <group group_id="B1">
          <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
          <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation given twice daily</description>
        </group>
        <group group_id="B2">
          <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
          <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
        </group>
        <group group_id="B3">
          <title>Open Label Patients With Type 2 Diabetes</title>
          <description>Adults with diet-controlled type 2 diabetes, treated with open-label Colchicine 0.6Mg Tab</description>
        </group>
        <group group_id="B4">
          <title>Evaluation Only Non-obese Adults</title>
          <description>Adults without obesity, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
        <group group_id="B5">
          <title>Evaluation Only Obese Adults</title>
          <description>Adults with obesity, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
        <group group_id="B6">
          <title>Evaluation Only Adults With Diet-controlled Type 2 Diabetes</title>
          <description>Adults with Diet-controlled Type 2 Diabetes, seen only for an evaluation visit, not given any medication and not followed longitudinally.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="10.0"/>
                    <measurement group_id="B2" value="47.3" spread="13.4"/>
                    <measurement group_id="B3" value="42.8" spread="13.4"/>
                    <measurement group_id="B4" value="37.2" spread="13.5"/>
                    <measurement group_id="B5" value="46.4" spread="11.9"/>
                    <measurement group_id="B6" value="47.9"/>
                    <measurement group_id="B7" value="44.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Sensitivity C-Reactive Protein</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="4.2"/>
                    <measurement group_id="B2" value="8.1" spread="7.4"/>
                    <measurement group_id="B3" value="9.63" spread="6.17"/>
                    <measurement group_id="B4" value="0.77" spread="0.80"/>
                    <measurement group_id="B5" value="3.08" spread="2.67"/>
                    <measurement group_id="B6" value="1.4"/>
                    <measurement group_id="B7" value="5.41" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity From FSIVGTT</title>
        <description>Change (3 month minus minus baseline) in insulin sensitivity value, calculated from frequently-sampled intravenous glucose tolerance tests by Bergman's Minimal Model using intent-to-treat. Higher values represent a better outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Randomized trial has 2 groups, open label only one group</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
            <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation, given twice daily</description>
          </group>
          <group group_id="O2">
            <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
            <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Open Label Patients With Type 2 Diabetes</title>
            <description>Patients With Type 2 Diabetes given open-label treatment with colchicine 0.6 Mg Tab</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity From FSIVGTT</title>
          <description>Change (3 month minus minus baseline) in insulin sensitivity value, calculated from frequently-sampled intravenous glucose tolerance tests by Bergman's Minimal Model using intent-to-treat. Higher values represent a better outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
          <population>Randomized trial has 2 groups, open label only one group</population>
          <units>10^-5*min^-1*mU^-1*mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-0.12" upper_limit="1.58"/>
                    <measurement group_id="O2" value="0.41" lower_limit="-0.90" upper_limit="1.72"/>
                    <measurement group_id="O3" value="-0.45" lower_limit="-1.58" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR Index</title>
        <description>Change (3 month minus minus baseline) in calculated homeostasis model of insulin sensitivity, calculated from derived from fasting glucose and insulin values = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5) using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>RCT has colchicine and placebo groups, open label is colchicine only.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
            <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation given twice daily</description>
          </group>
          <group group_id="O2">
            <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
            <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Open Label Patients With Type 2 Diabetes</title>
            <description>Patients With Type 2 Diabetes given open-label colchicine tablets twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR Index</title>
          <description>Change (3 month minus minus baseline) in calculated homeostasis model of insulin sensitivity, calculated from derived from fasting glucose and insulin values = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5) using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
          <population>RCT has colchicine and placebo groups, open label is colchicine only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.1" upper_limit="7.6"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.1" upper_limit="1.1"/>
                    <measurement group_id="O3" value="8.4" lower_limit="0.05" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in C-reactive Protein</title>
        <description>Change (3 month minus minus baseline) in High-Sensitivity C-reactive protein concentrations using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Patients randomized to colchicine or placebo for randomized controlled trial, but only open-label colchicine for patients with type 2 diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
            <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation given twice daily</description>
          </group>
          <group group_id="O2">
            <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
            <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Open Label Patients With Type 2 Diabetes</title>
            <description>Patients with type 2 diabetes given open-label colchicine tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in C-reactive Protein</title>
          <description>Change (3 month minus minus baseline) in High-Sensitivity C-reactive protein concentrations using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.</description>
          <population>Patients randomized to colchicine or placebo for randomized controlled trial, but only open-label colchicine for patients with type 2 diabetes</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.9" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-2.8" lower_limit="-4.1" upper_limit="-1.5"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-10.4" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Obese Adults With Metabolic Syndrome Randomized to Placebo</title>
          <description>Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation given twice daily</description>
        </group>
        <group group_id="E2">
          <title>Obese Adults With Metabolic Syndrome Randomized to Colchicine</title>
          <description>Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation given twice daily</description>
        </group>
        <group group_id="E3">
          <title>Open Label Patients With Type 2 Diabetes</title>
          <description>Open-label treatment with colchicine
Colchicine 0.6Mg Tab: Open-label colchicine</description>
        </group>
        <group group_id="E4">
          <title>Evaluation Only Non-obese Adults</title>
          <description>No treatment non-obese adults seen only for evaluation</description>
        </group>
        <group group_id="E5">
          <title>Evaluation Only Obese Adults</title>
          <description>No treatment obese adults seen only for evaluation</description>
        </group>
        <group group_id="E6">
          <title>Evaluation Only Adults With Diet-controlled Type 2 Diabetes</title>
          <description>No treatment adults with Type 2 Diabetes seen only for evaluation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Nausea, vomiting, or diarrhea</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Elevated Aspartate Aminotransferase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract</sub_title>
                <description>Viral syndrome, Upper Respiratory Illness</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatine Kinase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot trial to determine power calculations, so no definitive conclusions should be reached from this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jack Yanovski</name_or_title>
      <organization>NICHD, National Institutes of Health</organization>
      <phone>13014960858</phone>
      <email>yanovskj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

